A Randomized, Double-Blind, Placebo-Controlled Trial of Fufei Huazhuo Tongluo Formula Combined With Standardized Medicine in Patients With Anti-Synthetase Syndrome-Associated Interstitial Lung Disease

September 17, 2026 updated by: First People's Hospital of Hangzhou

A Prospective, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pragmatic Clinical Trial of Fufei Huazhuo Tongluo Formula Combined With Standardized Western Medicine for Glucocorticoid-Sparing Efficacy in Patients With Anti-Synthetase Syndrome-Associated Interstitial Lung Disease

The goal of this clinical trial is to learn if the traditional Chinese medicine formula "FuFei HuaZhuo TongLuo Granule" combined with standardized western medicine works to treat anti-synthetase syndrome-associated interstitial lung disease (ASS-ILD). It will also learn about the safety of this combined therapy. The main questions it aims to answer are:

Does the Chinese herbal formula plus standardized western medicine increase the proportion of patients who successfully reduce their glucocorticoid dose to a low maintenance level (prednisone ≤ 7.5 mg/day) at 24 weeks, compared with placebo plus standardized western medicine?

Does this herbal formula provide additional clinical benefits in terms of glucocorticoid sparing, delaying lung function decline, reducing infection risk, and improving traditional Chinese medicine syndrome scores?

What medical problems do participants have when taking this herbal formula?

Researchers will compare the Chinese herbal granule to a placebo granule (a look-alike substance that contains no active ingredients) to see if the herbal formula works to treat ASS-ILD. Both groups will receive standardized western medicine treatment based on disease severity.

Participants will:

Take the Chinese herbal granule or a placebo every day for 12 weeks

Visit the clinic at 8 time points: baseline, weeks 2, 4, 8, 12, 16, 20, and 24 for checkups and tests

Undergo pulmonary function tests (at baseline, week 12, and week 24) and high-resolution CT scans (at baseline, week 12, and week 24)

Receive disease activity assessments (MITAX score), traditional Chinese medicine syndrome evaluations, and safety monitoring (blood routine, liver and kidney function, adverse event recording) at each follow-up visit

Provide peripheral blood samples at weeks 0, 4, 12, and 24 for exploratory immunology and metabolomics research

Record their daily glucocorticoid dosage and concomitant medications throughout the study

Study Overview

Detailed Description

Background Anti-synthetase syndrome (ASS) is an autoimmune disease characterized by anti-aminoacyl-tRNA synthetase (ARS) antibodies and represents a major subtype of idiopathic inflammatory myopathy (IIM). Its clinical manifestations are heterogeneous, frequently involving the lungs, muscles, joints, and skin. Interstitial lung disease (ILD) is the most common and characteristic organ involvement, occurring in over 80% of patients and often presenting as the initial manifestation. In some patients, ASS-ILD follows a rapidly progressive course (RP-ILD), leading to acute respiratory failure within weeks or even days, with a 1-year survival rate of approximately 75%, making it a leading cause of critical illness and early death in rheumatology.

Current Western medical treatment for ASS-ILD relies on potent immunosuppression, primarily high-dose glucocorticoids combined with conventional immunosuppressants (e.g., cyclosporine, tacrolimus, cyclophosphamide). Biologics targeting B cells (rituximab) and JAK inhibitors have also been recommended for severe or refractory cases. However, long-term high-dose glucocorticoid and immunosuppressant use presents two major challenges: difficulty in tapering without disease relapse-rapid reduction often triggers pulmonary flares, while slow tapering increases cumulative toxicity, resulting in low successful tapering rates to safe doses within 24-40 weeks in real-world practice-and significant treatment-related toxicity, with exponentially increased risk of opportunistic infections (e.g., Pneumocystis jirovecii pneumonia, invasive fungal infections, cytomegalovirus infection).

In traditional Chinese medicine (TCM), ASS-ILD is classified as "lung impediment"or "lung atrophy". Based on long-term clinical experience, our group proposes that the core pathogenesis is "deficiency of lung collaterals as the root, with damp-heat, phlegm, and blood stasis as the manifestations." In the early stage, pathogenic heat and dampness obstruct the lung collaterals; as the disease progresses, chronic involvement leads to phlegm-stasis obstruction and eventually "collateral stasis with accumulation," which corresponds to reticular opacities, fibrotic nodules, and linear shadows on imaging. Guided by the principle of "unblocking collaterals to restore function," we developed the original Chinese herbal formula FuFei HuaZhuo TongLuo Granule (composed of Danggui, Qianghuo, Yinchen, Fangfeng, Cangzhu, Baizhu, Zhimu, Shengma, Gegen, Huangqin, Yiyiren, Ezhu, Dilong, Jiangcan, Gancao, etc.). Preliminary pilot and retrospective studies suggest that this formula may improve dyspnea, control TCM syndrome scores, facilitate glucocorticoid tapering, and reduce opportunistic infections.

Objectives The primary objective is to evaluate the rate of successful safe glucocorticoid (prednisolone or equivalent) tapering to a low maintenance dose (≤7.5 mg/day) at 24 weeks with the herbal formula plus standardized Western medicine, compared with placebo plus standardized Western medicine. Secondary objectives include exploring the clinical benefits on TCM syndrome scores, disease activity, reduction of Western drug side effects, and preservation of lung function; and investigating potential molecular targets and mechanisms through immunomics and multi-omics analyses of peripheral blood and other biospecimens.

Study Design Overview This is a single-center, randomized, double-blind, placebo-controlled pragmatic clinical trial (PCT). A total of 54 eligible patients will be enrolled and randomized in a 2:1 ratio using block randomization (stratified by baseline disease severity) to either the integrative medicine group (herbal plus standardized Western medicine) or the Western medicine alone group (placebo plus standardized Western medicine). The intervention consists of daily granule administration for 12 weeks, with a total follow-up of 24 weeks. There are 8 clinical visits: baseline (week 0) and weeks 2, 4, 8, 12, 16, 20, and 24. At each follow-up visit, all patients undergo disease activity assessment (MITAX score), traditional Chinese medicine (TCM) syndrome differentiation analysis, and safety monitoring, including complete blood count, liver and renal function tests, and adverse event recording. Peripheral blood samples are collected at weeks 0, 4, 12, and 24 for immunology and metabolomics research. Pulmonary function tests and high-resolution computed tomography (HRCT) scans are performed at baseline, week 12, and week 24. Throughout the study, daily glucocorticoid dosage and concomitant medications are recorded.

Study Type

Interventional

Enrollment (Estimated)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria: (1) Western medicine diagnostic criteria: meeting the 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathy, with positive anti-synthetase antibodies (e.g., anti-Jo-1, PL-7, PL-12, etc.), and confirmed interstitial lung disease (ILD) by high-resolution computed tomography (HRCT). (2) Traditional Chinese Medicine (TCM) syndrome differentiation criteria: meeting the criteria for either "damp-heat obstructing collaterals syndrome" or "collateral stasis with accumulation syndrome." Damp-heat obstructing collaterals syndrome: satisfying 2 major symptoms + 1 minor symptom + tongue and pulse manifestations, or 1 major symptom + 2 minor symptoms + tongue and pulse manifestations (major symptoms include heavy and aching muscles, joint aching, cough and wheezing with profuse phlegm, etc.; red tongue with yellow, greasy coating, and slippery, rapid pulse). Collateral stasis with accumulation syndrome: satisfying 2 major symptoms + 1 minor symptom + tongue and pulse manifestations, or 1 major symptom + 2 minor symptoms + tongue and pulse manifestations (major symptoms include stabbing muscle pain and weakness, fixed joint pain, shortness of breath and panting, etc.; dark tongue with ecchymotic spots, greasy coating, and deep, wiry or slippery pulse). (3) Age and sex: 18-70 years of age, both sexes eligible. (4) At screening, in a state of newly diagnosed or relapsed ASS-ILD, and receiving a glucocorticoid dose of ≥30 mg/day prednisone (or equivalent). (5) Informed consent: the patient or his/her legal representative voluntarily signs the written informed consent form.

Exclusion Criteria: (1) Concomitant other severe diseases: other active connective tissue diseases (e.g., SLE, RA, pSS, etc.); severe non-rheumatic cardiovascular diseases (e.g., uncontrolled heart failure, recent myocardial infarction), malignancy, or severe hepatic/renal dysfunction (ALT/AST > 3× ULN, Cr > 1.5× ULN). (2) Respiratory failure: At baseline, the presence of any one of the following criteria is defined as respiratory failure, and the patient should be excluded: Type I respiratory failure: at sea level and at rest, arterial blood gas showing PaO₂ < 60 mmHg with PaCO₂ ≤ 50 mmHg; Type II respiratory failure: at sea level and at rest, arterial blood gas showing PaO₂ < 60 mmHg with PaCO₂ > 50 mmHg. If the patient is already receiving high-flow oxygen therapy or non-invasive/invasive mechanical ventilation, respiratory failure is considered present regardless of blood gas values, and the patient should be excluded. (3) Interference from recent treatment history: receipt of hematopoietic stem cell transplantation within the past 3 months; continuous use of other systemic Chinese herbal decoctions or granules within 2 weeks before enrollment. (4) Special populations: pregnant or breastfeeding women. (5) Psychiatric or cognitive impairment: presence of severe psychiatric illness or cognitive impairment that prevents cooperation with clinical follow-up and assessments.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental: Chinese Herbal Formula plus Standardized Western Medicine

Participants receive FuFei HuaZhuo TongLuo Granule (one dose daily, orally, for 12 weeks) along with standardized Western medicine (glucocorticoids plus conventional immunosuppressants) adjusted according to a disease severity-based protocol.

FuFei HuaZhuo TongLuo Granule is a traditional Chinese medicine formulation provided as oral granules. One dose (divided into two equal portions) is taken orally in the morning and evening daily for 12 consecutive weeks. The granule contains the following herbal ingredients: Danggui, Qianghuo, Yinchen, Fangfeng, Cangzhu, Baizhu, Zhimu, Shengma, Gegen, Huangqin, Yiyiren, Ezhu, Dilong, Jiangcan, Gancao.

Placebo Comparator: Placebo Comparator: Placebo plus Standardized Western Medicine

Participants receive matching Placebo Granule (one dose daily, orally, for 12 weeks) along with the same standardized Western medicine protocol as the experimental arm.

Matching Placebo Granule is provided as oral granules with identical appearance, taste, odor, packaging, and labeling to the FuFei HuaZhuo TongLuo Granule. It contains inactive ingredients and is taken orally, one dose (divided into two equal portions) in the morning and evening daily for 12 consecutive weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Participants Achieving Glucocorticoid Tapering to ≤7.5 mg/day at Week 24
Time Frame: Week 24

Percentage of participants who successfully reduce their prednisone (or equivalent) maintenance dose to ≤7.5 mg/day at Week 24, without disease flare (as defined by objective pulmonary or imaging progression) and without initiating protocol-defined escalated salvage therapy.

Week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative Glucocorticoid Exposure Over 24 Weeks
Time Frame: Baseline up to Week 24

Area under the curve (AUC) of total glucocorticoid dose accumulated over the 24-week follow-up period.

Baseline up to Week 24
Proportion of Participants with ≥50% Reduction in Traditional Chinese Medicine Syndrome Score
Time Frame: Baseline and Week 24

Proportion of participants achieving at least a 50% reduction from baseline in the total Traditional Chinese Medicine (TCM) syndrome score at Week 24.

Baseline and Week 24
Proportion of Participants with Stable or Improved Forced Vital Capacity (FVC)
Time Frame: Baseline and Week 24

Proportion of participants with FVC% predicted value showing a decline of less than 5% from baseline (i.e., stable or improved) at Week 24.

Baseline and Week 24
Incidence of Severe Opportunistic Infections Requiring Hospitalization
Time Frame: Up to Week 24

Cumulative incidence of severe opportunistic infections (e.g., Pneumocystis jirovecii pneumonia, invasive fungal infections, cytomegalovirus infection) requiring hospitalization over the 24-week follow-up period.

Up to Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 10, 2026

Primary Completion (Estimated)

July 1, 2028

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

September 17, 2026

First Submitted That Met QC Criteria

September 17, 2026

First Posted (Actual)

September 23, 2026

Study Record Updates

Last Update Posted (Actual)

September 23, 2026

Last Update Submitted That Met QC Criteria

September 17, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe